Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...

President Donald Trump's new health care initiative aims to reduce prescription drug costs by targeting pharmacy benefit managers, commonly known as PBMs.

Diversified healthcare company CVS Health (NYSE:CVS) announced in Q1 CY2025, with sales up 7% year on year to $94.59 billion.

Gov. Gavin Newsom will seek to regulate prescription drug intermediaries, eight months after vetoing a similar bill.

Iowa, suggested Congress could once again move to overhaul PBMs’ controversial business practices after legislators pass ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

We don't need to dwell on the lack of detail behind Andrew Witty stepping down as CEO of UnitedHealth ( UNH) for "personal ...

Conflicts of interest in the health benefits space are both widespread and increasingly complex, meaning more fuel for more litigation.

While M&A activity has slowed in the tail end of the first quarter of 2025, including in healthcare, there have been several noteworthy ...

Sen. Josh Hawley, R-Mo., demanded Tuesday that Congress move to stop insurance companies from owning pharmacy benefit ...

Novo Nordisk inked an obesity deal worth up to $2.2 billion on Wednesday, and sent shares of Septerna into the stratosphere.

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...